Linked Life Data

19153568

Source:http://linkedlifedata.com/resource/pubmed/id/19153568

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-2-27
pubmed:abstractText
Little progress has been made in the treatment of small cell lung cancer over the past two decades. Superiority of combined irinotecan-cisplatin over standard etoposide-cisplatin in a Japanese phase III trial was not confirmed in two subsequent US studies. In this Practice Point we discuss a randomized, phase III trial by Hermes and colleagues, which included 220 patients with extensive-disease small cell lung cancer and showed superiority of carboplatin-irinotecan versus carboplatin-oral etoposide. In this trial, 47% of patients had a performance status > or = 3 and 35% were older than 70 years, which represents a typical clinical practice population of patients; however, oral administration of etoposide and an arbitrary dose reduction in elderly and unfit patients represent limitations of the study. A European trial of irinotecan-carboplatin versus intravenous etoposide-carboplatin has completed accrual and results will be analyzed in 2009. Although the results of the study by Hermes et al. are of interest, substitution of etoposide by irinotecan can not be recommended.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
Mar
pubmed:issn
1743-4262
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
134-5
pubmed:year
2009
pubmed:articleTitle
Should irinotecan or etoposide be used in combination with carboplatin for small cell lung cancer?
pubmed:affiliation
Department of Hematology and Oncology, Charité University Hospital, Campus Benjamin Franklin, Berlin, Germany.
pubmed:publicationType
Journal Article, Comment